Abstract:BackgroundBiliary tract cancer (BTC) is an uncommon but highly lethal malignancy with poor clinical outcomes. To promote the development of precision medicine for BTC, uncovering its genomic profile becomes particularly important. However, studies on the genomic feature of Chinese BTC patients remain insufficient. MethodsA total of 382 Chinese patients with BTC were enrolled in this study, including 71 with intrahepatic cholangiocarcinoma (ICC), 194 with extrahepatic cholangiocarcinoma (ECC), and 117 with gallbladder carcinoma (GBC). Genetic testing was performed by utilizing the next-generation sequencing (NGS) of 499 cancer-related genes and the results were compared to those of Western BTC patients (MSKCC cohorts). ResultsThe most prevalent genes were TP53 (51.6%), ARID1A (25.9%), KMT2C (24.6%), NCOR1 (17%), SMAD4 (15.2%), KRAS (14.9%), KMT2D (14.9%), ATM (14.1%), and APC (13.9%) in Chinese BTC patients. TP53, SMAD4, and APC were more prevalent in GBC, ECC, and ICC, respectively. In addition, 10.5% of Chinese BTC patients harbored pathogenic or likely pathogenic (P/LP) germline alterations in 41 genes, which were mainly related to DNA damage repair (DDR). Additionally, the genomic features of Chinese and Western BTC tumors were similar, with the exception of the notable difference in the prevalence of TP53, KRAS, IDH1, KMT2C, and SMAD4. Notably, Chinese BTC patients had high prevalence (57.1%) of actionable alterations, especially for those with ECC, and half (192/382) of them had somatic DDR alterations, with the prevalence of deleterious ones being significantly higher than their Western counterparts. Twenty-three percent of patients had a higher tumor mutational burden (TMB-H, over 10 mutations/MB), and TMB was significantly higher in those with deleterious DDR alterations and/or microsatellite instability-high. The most common mutational signature in BTC patients was Signature 1, and interestingly, Signatures 1, 4, and 26 were significantly associated with higher TMB level, but not with the survival of patients who had received immunotherapy in pan-cancer. ConclusionOur study elaborated the distinct germline and somatic genomic characteristics of Chinese BTC patients and identified clinically actionable alterations, highlighting the possibility for the development and application of precision medicine.

Ractical Guidelines For Molecular Testing Of Cholangiocarcinoma In Clinical Practice: Italian Experts' Position Paper

Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing

A Retrospective Analysis of Biliary Tract Cancer Patients Presented to the Molecular Tumor Board at the Comprehensive Cancer Center Munich

Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives

Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures

Molecular and Genomic Profiling of Lung Cancer in the Era of Precision Medicine: A Position Paper from the Italian Association of Thoracic Oncology (AIOT)

Clinical and Translational Research Challenges in Biliary Tract Cancers

Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA

Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy

Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions

A Review of Personalized Therapeutic Strategies

Practical considerations for pathological diagnosis and molecular profiling of cholangiocarcinoma: an expert review for best practices

Liquid biopsy in cholangiocarcinoma: Current status and future perspectives

Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers

Molecular tests and target therapies in oncology: recommendations from the Italian workshop

Impact of next-generation sequencing in biliary tract cancer treatment.

Mutational spectrum and precision oncology for biliary tract carcinoma

Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments

Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review

Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer

Recent Advancement in Diagnosis of Biliary Tract Cancer through Pathological and Molecular Classifications